Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month
Axsome Therapeutics (NASDAQ: AXSM) is partnering with Mental Health America (MHA) to promote Mental Health Month in May 2025. As part of MHA's "Light Up Green" initiative, Axsome's NYC headquarters at One World Trade Center will be illuminated in green to raise mental health awareness.
The collaboration highlights concerning mental health statistics in the US: nearly 1 in 4 adults live with mental illness, and more than 1 in 8 people aged 12 or older reported feeling depressed in the past two weeks. Almost 90% of people with depression experience difficulties with work, home, or social activities.
The initiative provides various resources including MHA's Mental Health Month Action Guide, ADAA's Mental Health Webinars, and NAMI's awareness campaign. The 988 Suicide & Crisis Lifeline is available 24/7 for those in crisis.
Axsome Therapeutics (NASDAQ: AXSM) collabora con Mental Health America (MHA) per promuovere il Mese della Salute Mentale a maggio 2025. Nell'ambito dell'iniziativa "Light Up Green" di MHA, la sede di Axsome a New York, situata al One World Trade Center, sarà illuminata di verde per sensibilizzare sull'importanza della salute mentale.
La collaborazione mette in luce dati preoccupanti sulla salute mentale negli Stati Uniti: e oltre 1 persona su 8 di età pari o superiore a 12 anni ha dichiarato di essersi sentita depressa nelle ultime due settimane. Quasi il 90% delle persone con depressione affronta difficoltà nel lavoro, nella vita domestica o nelle attività sociali.
L'iniziativa offre diverse risorse, tra cui la Guida alle Azioni per il Mese della Salute Mentale di MHA, i webinar sulla salute mentale dell'ADAA e la campagna di sensibilizzazione di NAMI. La linea telefonica 988 Suicide & Crisis Lifeline è disponibile 24 ore su 24, 7 giorni su 7, per chi si trova in crisi.
Axsome Therapeutics (NASDAQ: AXSM) se asocia con Mental Health America (MHA) para promover el Mes de la Salud Mental en mayo de 2025. Como parte de la iniciativa "Light Up Green" de MHA, la sede de Axsome en Nueva York, ubicada en One World Trade Center, se iluminará de verde para aumentar la conciencia sobre la salud mental.
La colaboración destaca estadísticas preocupantes sobre la salud mental en EE. UU.: casi 1 de cada 4 adultos vive con una enfermedad mental y más de 1 de cada 8 personas de 12 años o más reportaron sentirse deprimidas en las últimas dos semanas. Casi el 90% de las personas con depresión experimentan dificultades en el trabajo, el hogar o actividades sociales.
La iniciativa ofrece varios recursos, incluyendo la Guía de Acción para el Mes de la Salud Mental de MHA, los seminarios web de salud mental de ADAA y la campaña de concienciación de NAMI. La línea de ayuda 988 Suicide & Crisis Lifeline está disponible 24/7 para quienes estén en crisis.
Axsome Therapeutics (NASDAQ: AXSM)는 Mental Health America (MHA)와 협력하여 2025년 5월 정신 건강의 달을 홍보합니다. MHA의 "Light Up Green" 캠페인의 일환으로, Axsome의 뉴욕 본사인 원 월드 트레이드 센터가 녹색 조명으로 밝혀져 정신 건강 인식을 높일 예정입니다.
이번 협력은 미국 내 정신 건강에 관한 우려스러운 통계를 강조합니다: 성인 4명 중 거의 1명이 정신 질환을 겪고 있으며, 12세 이상 인구의 8명 중 1명 이상이 지난 2주간 우울감을 느꼈다고 보고했습니다. 우울증 환자의 거의 90%는 직장, 가정 또는 사회 활동에서 어려움을 겪고 있습니다.
이 캠페인은 MHA의 정신 건강의 달 행동 가이드, ADAA의 정신 건강 웨비나, NAMI의 인식 캠페인 등 다양한 자원을 제공합니다. 위기 상황에 처한 사람들을 위해 24시간 운영되는 988 자살 및 위기 상담 전화가 마련되어 있습니다.
Axsome Therapeutics (NASDAQ: AXSM) s'associe à Mental Health America (MHA) pour promouvoir le Mois de la Santé Mentale en mai 2025. Dans le cadre de l'initiative "Light Up Green" de MHA, le siège d'Axsome à New York, situé au One World Trade Center, sera illuminé en vert pour sensibiliser à la santé mentale.
Cette collaboration met en lumière des statistiques préoccupantes sur la santé mentale aux États-Unis : près d'un adulte sur quatre vit avec une maladie mentale et plus d'une personne sur huit âgée de 12 ans ou plus a déclaré s'être sentie déprimée au cours des deux dernières semaines. Près de 90 % des personnes souffrant de dépression rencontrent des difficultés au travail, à la maison ou dans leurs activités sociales.
L'initiative propose diverses ressources, notamment le guide d'action du Mois de la Santé Mentale de MHA, les webinaires sur la santé mentale de l'ADAA et la campagne de sensibilisation de NAMI. La ligne d'assistance 988 Suicide & Crisis Lifeline est disponible 24h/24 et 7j/7 pour les personnes en crise.
Axsome Therapeutics (NASDAQ: AXSM) arbeitet mit Mental Health America (MHA) zusammen, um den Monat der psychischen Gesundheit im Mai 2025 zu fördern. Im Rahmen der "Light Up Green"-Initiative von MHA wird der Hauptsitz von Axsome in New York am One World Trade Center grün beleuchtet, um das Bewusstsein für psychische Gesundheit zu stärken.
Die Zusammenarbeit hebt besorgniserregende Statistiken zur psychischen Gesundheit in den USA hervor: fast 1 von 4 Erwachsenen lebt mit einer psychischen Erkrankung und mehr als 1 von 8 Personen ab 12 Jahren gab an, sich in den letzten zwei Wochen depressiv gefühlt zu haben. Fast 90 % der Menschen mit Depressionen haben Schwierigkeiten bei der Arbeit, zu Hause oder in sozialen Aktivitäten.
Die Initiative bietet verschiedene Ressourcen, darunter den Aktionsleitfaden zum Monat der psychischen Gesundheit von MHA, die Mental Health Webinare der ADAA und die Aufklärungskampagne von NAMI. Die 988 Suicide & Crisis Lifeline ist rund um die Uhr für Menschen in Krisensituationen erreichbar.
- None.
- None.
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is joining with Mental Health America (MHA) and the broader mental health advocacy community in a consolidated effort to raise awareness and promote action during May’s Mental Health Month.
On May 1, as part of Mental Health America’s “Light Up Green” initiative, Axsome’s New York City headquarters, the One World Trade Center building, will be lit in green, the color for mental health awareness, and through the building’s Spireworks program.
“Mental Health America’s 2024 data confirm what we already know to be true: We are in a mental health crisis that can affect anyone, anywhere,” said Schroeder Stribling, president and CEO of Mental Health America. “Mental health is health, and it affects us all. There are many social and environmental stressors impacting individuals and families across the country—whether you’re someone who lives in a remote rural community, a young person facing online bullying, or someone who is bearing the weight of family financial strain, one’s mental health is directly impacted. We hope that our Mental Health Month resources shine a light on these issues and support the needs of those who are seeking to understand and improve their mental health.”
The impact of mental health conditions is significant in the United States, with nearly 1 in 4 adults in the U.S. living with a mental illness.1 More than 1 in 8 people aged 12 or older in the U.S. felt depressed in the past two weeks, according to a recent study, highlighting the ubiquity and significant impact that depression has in the U.S.2 In particular, nearly
Axsome’s mission is to improve the lives of individuals living with serious CNS conditions that are difficult to treat or have limited treatment options by developing innovative evidence-based treatments that offer meaningful improvements to the standard of care. And, in the spirit of this year’s Mental Health Month theme of “Turning Advocacy into Action,” Axsome is highlighting the following resources for individuals and communities to take action for themselves or others:
- Mental Health America’s Mental Health Month Action Guide (https://mhanational.org/mental-health-month/action-guide/). MHA's work is driven by its commitment to promote mental health as a critical part of overall wellness, including prevention services for all; early identification and intervention for those at risk; and integrated care, services, and support for those who need them, with recovery as the goal. Resources to take action for your or others’ personal mental well-being provided by the MHA include its Online Screening Tools, Youth Leadership Programs and the opportunity to become a mental health advocate.
- Anxiety and Depression Association of America’s (ADAA) Mental Health Webinars (https://adaa.org/resources-news/from-adaa-experts/webinars) can address your questions about mental health conditions. ADAA’s mission focuses on improving quality of life for those with anxiety, depression, OCD, PTSD, and co-occurring disorders through education, practice, and research. ADAA’s resources also include free online peer support groups.
- National Alliance on Mental Illness’ (NAMI) Mental Health Awareness Month Campaign (https://www.nami.org/get-involved/awareness-events/mental-health-awareness-month/). NAMI is the nation’s largest grassroots mental health organization dedicated to building better lives for the millions of Americans affected by mental illness. NAMI is also asking people to share their story as part of their “In Every Story, There’s Strength” campaign. You can learn more about the campaign and submit a short story to NAMI here.
If you or someone you know is in crisis, the 988 Suicide & Crisis Lifeline (https://988lifeline.org/) is a free confidential support service available 24 hours a day, 7 days a week across the United States. When people call, text, or chat 988, they will be connected to trained counselors that are part of the existing Lifeline network. These trained counselors will listen, understand how their problems are affecting them, provide support, and connect them to resources if necessary.
About Axsome Therapeutics
Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.
Forward Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s Sunosi®, Auvelity®, and Symbravo® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of Sunosi, Auvelity, and Symbravo and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investors:
Mark Jacobson
Chief Operating Officer
(212) 332-3243
mjacobson@axsome.com
Media:
Darren Opland
Director, Corporate Communications
(929) 837-1065
dopland@axsome.com
References:
- SAMHSA (2023) Key Substance Use and Mental Health Indicators in the United States: Results from the 2023 National Survey on Drug Use and Health, Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration.
- Brody DJ, Hughes JP. Depression prevalence in adolescents and adults: United States, August 2021–August 2023. 2025 Apr; (527)1–11. DOI: https://dx.doi.org/10.15620/cdc/174579.
FAQ
What is Axsome Therapeutics (AXSM) doing for Mental Health Month 2025?
What mental health statistics did AXSM's press release reveal about the US?
What resources is Axsome Therapeutics promoting for mental health support?
How can people access mental health crisis support through AXSM's promoted resources?
